President Donald Trump speaks speaks on the latest developments of the coronavirus outbreak, while flanked by White House coronavirus response coordinator Debbie Birx (L), and U.S. Surgeon General Jerome Adams (R), in the James Brady Press Briefing Room at the White House March 19, 2020. (Photo by Chip Somodevilla/Getty Images)
President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases.
The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.
"We're going to be able to make that drug available almost immediately," Trump said.
The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.
He also tempered the president's optimism about the still-untested solution.
"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."
New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.
"The therapies are something we could move on much faster potentially," Trump said.
He claimed the administration "slashed red tape" to develop new vaccines and therapies.
The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks.
"If we find that we need something, then we will do that," he said.
Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak.
The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.
"We continue our relentless effort to defeat the Chinese virus," Trump said.
Instagram CEO Adam Mosseri faced a bipartisan Congressional grilling this week as the Senate inquired about safety practices for protecting the mental wellbeing of young people on the platform. Sen. Marsha Blackburn (R-Tenn.) joined Cheddar to talk about the hearing and how she was disappointed in Instagram coming unprepared with relevant information or documents. Blackburn also offered concern that the platform could continue with building a kids-only version despite having drawn significant opposition from the public.
The Great Resignation has shown some signs of slowing in October with the number of those who quit their jobs falling by 4.7 percent to 4.16 million. This comes as worker strikes and calls for unionization ramp up. Jane Oates, president at WorkingNation joined Cheddar's "Opening Bell" to discuss the implications.
U.S. markets opened lower despite positive jobs data, which saw weekly claims drop to a 52-year low. Kevin Nicholson, Co-CIO Global Fixed Income, RiverFront Investment Group joined Cheddar's Opening Bell to discuss the labor market, inflation, and the impact of the Omicron variant on global markets.
A packed Thursday pod: Carlo and Baker cover the latest developments in the Ghislaine Maxwell, Jussie Smollett and Elizabeth Holmes trials. Plus, Dems are losing the Hispanic vote, Boris Johnson in trouble again, and is it possible that Adele has peaked?
Jim Bruderman, Vice Chairman at 1879 Advisors, joins Cheddar News' Closing Bell, where he says investors experienced a 'panic attack' last week with the spread of the Omicron variant and the Fed's tapering plans. As a result, he says we're now seeing stocks climb due to a growing comfort level toward both developments.
Adam Mosseri, head of Instagram, faced withering questions on Capitol Hill about the reports the social media app was aware of the severe mental health impacts it was having on teenage girls. Karen Kornbluh, the director of digital innovation and democracy for the German Marshall Fund, joined Cheddar to discuss the rare show of bipartisan outrage on display at the Senate hearing. "The senators came really loaded for bear on both sides of the aisle," she said. Kornbluh explained how senators like Richard Blumenthal (D-Conn.) set up fake Instagram accounts with teen girl profiles in order to research the effects firsthand.
The Biden administration will not send an official U.S. delegation to the 2022 Winter Olympics in Beijing as a statement against China's "ongoing genocide and crimes against humanity in Xinjiang." Weifeng Zhong, senior research fellow at George Mason University's Mercatus Center, joins Cheddar News to discuss the boycott.
